BUB (BUB) News
Follow BUB (BUB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BUB: Permanent FDA approval enables ongoing US supply and expansion opportunities for infant formula
Permanent FDA approval was secured for three infant formula products, enabling ongoing US market access and positioning the company as a leading non-US supplier. The authorisation supports growth, product innovation, and
REGULATION | Sep 10, 2026, 01:25 PM UTC
L
BUB: Permanent FDA approval secures U.S. market access and unlocks new growth and innovation opportunities
Permanent FDA authorization for three SKUs enables accelerated U.S. growth, validates the supply chain, and supports expansion into premium infant formula segments. The company now holds a strong national presence, is pu
REGULATION | Sep 10, 2026, 02:24 AM UTC
H
BUB: Permanent FDA authorisation enables expansion in the US infant formula market and contract manufacturing
Permanent FDA authorisation for goat, grass-fed, and essential infant formula products positions the company as a key non-US supplier in the US market. This milestone enables expansion into high-growth segments and contr
CENTRAL_BANK | Sep 10, 2026, 12:09 AM UTC
L
Bell Potter raises Bubs Australia price target 36% to A$0.19
Bell Potter raised its Bubs Australia price target by 36% to A$0.19 per share.
EQUITY | Sep 07, 2026, 10:54 PM UTC
L
Bubs Australia price target raised to A$0.20/share
Shaw & Partners raised its Bubs Australia price target by 33% to A$0.20 per share.
EQUITY | Sep 07, 2026, 10:10 PM UTC
M
Bubs Australia gets permanent FDA authorisation for US infant formula sales
Bubs Australia secured permanent authorisation from the U.S. Food and Drug Administration to sell three infant formula products in the U.S., sending shares up 30% to their highest close since mid-February.
REGULATION | Sep 07, 2026, 07:20 AM UTC
M
Bubs Australia gets permanent FDA authorisation for US infant formula sales
Bubs Australia said it secured permanent authorisation from the U.S. Food and Drug Administration to sell three infant formula products in the country.
REGULATION | Sep 07, 2026, 06:32 AM UTC
M
Bubs Australia secures permanent U.S. FDA approval for infant formula
Bubs Australia Ltd secured permanent approval from the U.S. FDA for its infant formula.
REGULATION | Sep 07, 2026, 01:35 AM UTC
L
Bubs Australia price target cut to A$0.15 by Shaw & Partners
Shaw & Partners cut its Bubs Australia price target 6.3% to A$0.15 a share.
EQUITY | Aug 27, 2026, 11:02 PM UTC
M
BUB revenue rises 9.2% to AUD 112M
BUB reported revenue up 9.2% to AUD 112M. The U.S. led growth, with margins expected to normalize as one-offs subside.
EQUITY | Aug 27, 2026, 03:07 AM UTC
M
BUB revenue up 9.2% to AUD 112M; EBITDA improves
BUB revenue rose 9.2% to AUD 112M. Underlying EBITDA improved. The U.S. leads growth and an FDA approval is close.
REGULATION | Aug 27, 2026, 02:26 AM UTC
L
Bubs Australia posts FY EBITDA of AUD -1.8 million
Bubs Australia reported FY EBITDA of AUD -1.8 million.
EQUITY | Aug 27, 2026, 01:41 AM UTC
M
BUB posts 9.2% revenue rise to $111.9M, net loss $4.6M
BUB revenue rose 9.2% to $111.9M, but it reported a net loss of $4.6M.
EQUITY | Aug 26, 2026, 10:34 PM UTC